Press communication
Lund, Sweden, 5 February 2024
This is a translation of the Swedish press release published 2024-02-05

Neola Medical AB (publ) invites to presentation of the Q4-report of 2023, Wednesday the 14th of February 2024 at 11am CET (11.00). The presentation will be held online as a video conference. The Q4-report will be published the same morning.

Neola Medical publishes the Q4-report in the morning the 14th of February 2024. We hereby invite investors, analysts, and journalists to a combined report presentation and video conference Wednesday the 14th of February 2024 at 11am CET (11.00). The report will be presented by CEO Hanna Sjostrom and CFO Christian Gyllenberg. After the presentation it will be possible for those who participate to ask questions live through the chat.

Please sign up in advance by sending an e-mail to Andriana Molins, CEO Assistant at After sign-up you will be invited to the video conference by receiving a link to a Microsoft Teams meeting. You can also send questions in advance to the same e-mail address.
For further questions after the presentation, contact CFO Christian Gyllenberg through below contact details.

The report and report presentation will be available at Neola Medical’s website:

Read the press release in Swedish here: Neola Medical bjuder in till presentation av bokslutskommuniké 2023

For further information, contact:
Hanna Sjöström, CEO Neola Medical, phone: +46 760-10 71 16, e-mail:
Christian Gyllenberg, CFO Neola Medical, phone: +46 727-44 50 10, e-mail:

Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants’ lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at The company’s Certified Adviser is FNCA Sweden AB.